Deals
While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Advanced Medical Solutions Group plc announces its unaudited interim results for the six months ended 30 June 2019.
Amphion Innovations plc announces that 1,150,000 shares in Partner Company, Polarean Imaging plc have been sold for partial repayment of the loan facility originally announced on 5 June 2014 and most recently amended as announced on 1 April 2019.
InDevR, Inc. announced that it has raised a $7 million Series A round of equity financing from Adjuvant Capital.
Building on its unique six-year relationship with Avalon Ventures, GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for celiac disease.
Proceeds to fund multi-centre study of STAR Mapping to improve outcomes of persistent Atrial Fibrillation treatment
Flexion Therapeutics, Inc. and Xenon Pharmaceuticals Inc. announced that the companies have entered into a definitive agreement that provides Flexion with the global rights to develop and commercialize XEN402, a NaV1.7 inhibitor, for the management of post-operative pain.
Lightcast Discovery Ltd announces that it has raised £1.3 m in seed financing from private investors to develop the capabilities and applications of its platform including continuing to expand its range of pilot studies.
4BIO Ventures II fund solely focused on advanced therapies targeting $150 million final close
ADC Therapeutics SA announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common shares.
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.